Targeted therapy with apatinib in a patient with relapsed small cell lung cancer: A case report and literature review.

ABSTRACT:

Rationale

Small cell lung cancer (SCLC) is a lethal malignancy. Once relapsed, the disease is irreversible and most of the patients will die of cancer aggravation in 1 to 2 months. In the past several decades, little progress has been made in the systemic treatment of SCLC. Apatinib, as a novel small-molecule tyrosine kinase inhibitor specifically targeting the vascular endothelial growth factor receptor 2 (VEGFR2), has achieved progress in treatment of a variety of cancers. However, there has been no report of the targeted therapy with apatinib in SCLC yet.

Patient concerns

A 63-year-old man, an ex-smoker, presented with a slight hoarseness and cough. The patient was admitted to our department with a primary diagnosis of SCLC at an extensive stage (ES-SCLC). After 17 months

SUBMITTER: Zhao J 

PROVIDER: S-EPMC5815779 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature